Vnitr Lek 2016, 62(Suppl 2):6-9

Real data o viral hepatitis C therapy in the Czech Republic

Libuše Husová
Centrum kardiovaskulární a transplantační chirurgie, Brno

We reported the first real data about efficacy of interferon-free therapy of chronic hepatitis C in the Czech Republic. Patients were treated with combined therapy of paritaprevir/ritonavir + ombitasvir + dasabuvir with or without ribavirin. There were 109 patients, predominantly men - 62 (57 %), most of them infected by genotype 1b - 101 patients (93 %), minority infected by genotypes 1a (6/109, 5 %) and 4 (2/109, 2 %). Both treatment-naive (43/109, 39 %), and treatment-experienced patients (66/109, 61 %) were treated. Sustained virological response 12 weeks after therapy termination (SVR12) was 100 %, with exclusion of patients with other reason than virological treatment failure.

Keywords: dasabuvir; chronic hepatitis C; ombitasvir; paritaprevir, rinonavir; ribavirin

Received: September 2, 2016; Accepted: September 12, 2016; Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husová L. Real data o viral hepatitis C therapy in the Czech Republic. Vnitr Lek. 2016;62(Supplementum 2):6-9.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. [European Association for the Study of Liver]. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61(2): 373-395. Go to original source... Go to PubMed...
    2. [European Association for the Study of Liver]. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63(1): 199-236. Go to original source... Go to PubMed...
    3. AASLD recommendation for testing, managing, and treating hepatitis C. Dostupné z WWW: <www.hcvguidelines.org>. [15.8.2016].
    4. Urbánek P, Husa P, Šperl J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Klin Mikrobiol Inf Lek 2015; 21(3): 83-98.
    5. Urbánek P. Exviera, Viekirax. Gastroent Hepatol 2015; 69(1): 75-80. Go to original source...
    6. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1594-1603. Go to original source... Go to PubMed...
    7. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370(21): 1983-1992. Go to original source... Go to PubMed...
    8. Wyles DL, Sulkowski MS, Eron JJ et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology 2014; 60(Suppl 1): 1136A. Conference Report: <http://www.natap.org/2014/AASLD/AASLD_28.htm>.
    9. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1604-1614. Go to original source... Go to PubMed...
    10. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147(2): 359-365. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.